article thumbnail

Biologics License Application for 21-Valent Pneumococcal Vaccine Granted FDA Priority Review

Pharmaceutical Commerce

Merck’s Biologics License Application for V116, a 21-valent pneumococcal conjugate vaccine, was given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024.

article thumbnail

Dyadic expands Covid-19 licence with Rubic to bolster vaccine production in Africa

Pharmaceutical Technology

The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

India’s CDSCO approves Bharat Biotech’s intra-nasal vaccine for Covid-19

Pharmaceutical Technology

India’s Central Drugs Standard Control Organisation (CDSCO) has granted approval for Bharat Biotech’s BBV154 vaccine for treating Covid-19. BBV154 is claimed to be the first intra-nasal vaccine for Covid-19 in the world.

article thumbnail

Noxopharm in-licenses novel RNA tech for drug discovery and vaccines

BioPharma Reporter

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52
article thumbnail

Bavarian Nordic completes travel vaccine deal with Emergent

Pharmaceutical Technology

Bavarian Nordic has completed the acquisition of Emergent BioSolutions ’ travel vaccine portfolio for an upfront payment of $274m, with the potential for the total value to rise to $384m. Following the completion of the deal, Bavarian Nordic now boasts the only oral vaccine licensed by the U.S.

article thumbnail

FDA decision on Pfizer’s maternal RSV vaccine expected by August

BioPharma Reporter

The US Food and Drug Administration (FDA) has accepted Pfizerâs Biologics License Application (BLA) for its maternal RSV vaccine under priority review. If approved, the vaccine will become the first RSV vaccine for pregnant women to protect against RSV in infants.

article thumbnail

Fierce Pharma Asia—Eisai eyes Leqembi surge; Takeda nabs Alzheimer's drug option; BIOSECURE Act advances

Fierce Pharma

Takeda put down $100 million upfront for an option to license an anti-amyloid vaccine from AC Immune. Following a reportedly bullish assessment from Medicare, Eisai has projected a significant sales increase for Leqembi. Eisai has projected a significant sales increase for Leqembi. And more.

Sales 71